BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• 

  Earnings

  J&J Sets Tariff Tone as Q1 Earnings Begin To Roll In

  Analysts have had to throw out their assumptions for the biopharma industry’s recovery heading into the first quarter earnings period given the ongoing tariff drama.

  April 16, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Drug pricing

  ‘Finally, Some Good News’: Trump Signals Support for Removing IRA’s Pill Penalty

  Analysts are “cautiously optimistic” about Trump’s executive order, noting that changes to the IRA drug price negotiation program will still require Congressional action before being implemented.

  April 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Bluebird’s Second Suitor, Ayrmid, Fails To Produce an Offer

  Despite making an unsolicited bid for gene therapy maker bluebird bio, Ayrmid failed to deliver a binding offer after weeks of due diligence. Bluebird’s board recommended that it go with Carlyle and SK Capital Partner’s original offer to take the company private for $30 million.

  April 16, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Compensation

  Top 6 Highest-Paid Pharma CEOs in 2024

  Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

  April 16, 2025

   · 

  7 min read

   · 

  Annalee Armstrong
• 

  Europe

  With Tariffs Looming, EU and US Pharmas Make Demands of European Commission

  Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.

  April 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Podcast

  Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed

  Donald Trump takes biopharma on a tariff-themed rollercoaster ride; J&J kicks off the Q1 earnings season; experts express concern about the FDA’s future; Pfizer’s obesity setback could be Viking’s gain; and BioSpace reveals the highest paid pharma CEOs.

  April 16, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Rare diseases

  Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year

  The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a rare disease that affects the entire body and produces a wide range of symptoms.

  April 16, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Clinical research

  Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

  Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

  April 16, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  Former FDA Officials Sound Alarm: Visible Changes May Be ‘Tip of the Iceberg’

  In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER director spoke to analysts about potential implications for drug review timelines and agency morale.

  April 16, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• Press Releases

  Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

  April 16, 2025

   · 

  7 min read